Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 21 years;~2. Undergoing thrice-weekly maintenance HD for ≥ 3 months;~3. Able to speak either English or Spanish;~4. BDI-II score ≥ 15; and~5. Meets diagnostic criteria for either current major depressive episode or dysthymia on the MINI.~Exclusion Criteria:~1. Active suicidal intent;~2. Ongoing psychotherapy or current treatment with certain anti-depressant drugs;~3. Evidence of cognitive impairment on Mini-Cog;~4. Present or past psychosis or bipolar disorder I or II on the MINI;~5. Alcohol or substance abuse diagnosed on the MINI or history of such abuse in the past three months;~6. Life expectancy \< 3 months, in the judgment of the site principal investigator;~7. Anticipated to receive living related donor kidney transplantation within 3 months;~8. Pregnancy, or lactation, or women of childbearing age not willing to use adequate birth control;~9. Clinical and/or laboratory evidence of chronic liver disease;~10. History of significant active bleeding in the past three months, such as hospitalization for gastrointestinal bleeding;~11. Current use of class I anti-arrhythmic medications (e.g., propafenone, flecainide), pimozide, monoamine oxidase inhibitors, reserpine, guanethidine, cimetidine, tri-cyclic anti-depressants, triptans, tramadol, linezolid, tryptophan, and St. John's wort; and~12. Known hypersensitivity to sertraline.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Engagement Interview (Type: ACTIVE_COMPARATOR): Subjects will be randomly assigned to engagement interview or a control visit.Trained CBT therapists at each of the three sites will conduct the engagement interview. The session will be aimed at improving the acceptance of the diagnosis of depression by patients and treatment for the same.
- Control Visit (Type: NO_INTERVENTION): Subjects will be randomly assigned to engagement interview or a control visit. Individuals assigned to control visit will be scheduled for a follow-up discussion with a member of the research team. During this session, they will be informed of the diagnosis of major depression or dysthymia, the options for treatment available through the clinical trial, and alternatives should they decline participation in the clinical trial.
- Cognitive Behavioral Therapy (Type: ACTIVE_COMPARATOR): The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization.~Individuals will undergo 10 CBT sessions of 60 minutes each, by a trained therapist in the dialysis facility (8 weekly sessions; then every other week x 2). The CBT will be administered while the patient is undergoing HD; however, alternative arrangements will be made upon individual patient's preferences.
- Antidepressant Drug Therapy (Type: ACTIVE_COMPARATOR): The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization. Anti-Depressant Drug Therapy will be delivered with sertraline, a selective serotonin reuptake inhibitor, and the dose will be titrated using the Measurement Based Care Protocol.
- Observational Cohort (Type: NO_INTERVENTION): Subjects who (1) are not willing to participate in the clinical trial and (2) do not find any treatment acceptable outside the clinical trial will be invited to participate in the prospective observational cohort for serial assessment of depressive symptoms.These subjects will only undergo assessment of severity of depressive symptoms at weeks 0, 6, and 12 using QIDS-C.

Based on this trial design, predict the completion outcome and termination type (if applicable).